CereMark touts new patents for PET Alzheimer's agent

2019 10 23 18 31 0645 Patent Stamp 20191023184409

Radiopharmaceutical developer CereMark announced that additional patents have been awarded to the University of California, Los Angeles (UCLA) for a PET agent that the company licensed from the university for the imaging of Alzheimer's disease.

The patents are associated with F-18 flornaptitril (also known as F-18 FDDNP), a biomarker for the detection, development, and progression of Alzheimer's disease, as well as chronic traumatic encephalopathy and other neurodegenerative diseases.

The patents cover a synthesizing method that allows for high radiochemical yields and short manufacturing times for administration.

CereMark is UCLA's only licensee for the development and commercialization of F-18 flornaptitril, and the company is preparing for a phase 3 clinical multisite study required for U.S. Food and Drug Administration approval.

Page 1 of 543
Next Page